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Abstract Purpose: The signal transducer and activator of transcription 3 (STAT3) is frequently overex-
pressed inmost cancers, propagates tumorigenesis, and is a key regulator of immune suppression
in cancer patients.We sought to determine the incidence of phosphorylated STAT3 (p-STAT3)
expression in malignant gliomas of different pathologic types, whether p-STAT3 expression is a
negative prognostic factor, and whether p-STAT3 expression influences the inflammatory
response within gliomas.
Methods:Using immunohistochemical analysis, wemeasured the incidence of p-STAT3expres-
sion in 129 patients with gliomas of various pathologic types in a glioma tissue microarray.We
categorized our results according to the total number of p-STAT3^ expressing cells within the
gliomas and correlated this number with the number of infiltratingTcells and Tregulatory cells.
We then evaluated the association between p-STAT3 expression and median survival time using
univariate and multivariate analyses.
Results:We did not detect p-STAT3 expression in normal brain tissues or low-grade astrocyto-
mas.We observed significant differences in the incidence of p-STAT3 expression between the
different grades of astrocytomas and different pathologic glioma types. p-STAT3 expression
was associated with the population of tumor-infiltrating immune cells but not with that of T
regulatory cells. On univariate analysis, we found that p-STAT3 expression within anaplastic
astrocytomas was a negative prognostic factor.
Conclusions: p-STAT3 expression is common within gliomas of both the astrocytic and oligo-
dendroglial lineages and portends poor survival in patients with anaplastic astrocytomas.
p-STAT3 expression differs significantly between gliomas of different pathologic types and
grades and correlated with the degree of immune infiltration.
A key transcription factor, signal transducer and activator of
transcription (STAT3), has been shown to drive the fundamen-
tal components of tumorigenesis and metastasis by preventing
apoptosis (by increasing survivin, BCL-XL, and MCL1 expres-
sion) and enhancing proliferation (by increasing c-Myc and
cyclin D1/D2 expression; ref. 1), angiogenesis (by increasing
vascular endothelial growth factor and hypoxia-inducible
factor-1a expression), invasion (by increasing matrix metal-
loproteinase-2 and matrix metalloproteinase-9 expression), and
metastasis (2, 3). Growth factors and cytokines, including
interleukin (IL)-6, can activate Janus kinase 2, which subse-
quently activates STAT3 by phosphorylating the tyrosine residue
in the STAT3 transactivation domain (4). Phosphorylated STAT3
(p-STAT3) then translocates into the nucleus and induces the
expression of a variety of target genes. IL-6, which is expressed
in the central nervous system (CNS) under a variety of con-
ditions, such as hypoxia (5), traumatic and metabolic injury (6),
and inflammation (7), has been shown to attract T cells to the
CNS (8). Specifically, IL-6 signaling by means of STAT3 is tightly
linked to the homing and migrational capacity of T cells (8).
STAT3 is constitutively overexpressed in a variety of cancers;
for instance, in melanoma, 81% of CNS metastases express
activated STAT3 (9). Preclinical studies using decoy antisense
STAT3 oligonucleotides, dominant-negative vectors, and small-
molecule inhibitors have provided convincing evidence that
STAT3 is highly relevant to the growth and survival of many
tumor types (10–20), including gliomas (14), in vitro and in vivo.
STAT3 is also a key regulator of immune suppression; it is
believed to regulate anti-inflammatory responses by suppressing
macrophage activation (21–23) and limiting inflammatory
responses (24). The tumor microenvironment induces STAT3
activity in tumor-associated immune cells (25, 26). STAT3
activity within natural killer cells and neutrophils directly
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reduces their cytotoxicity, whereas STAT3 activity in dendritic
cells reduces the expression of MHC II, CD80, CD86, and IL-12,
rendering the dendritic cells unable to stimulate T cells and
generate antitumor immunity (27). By ablating STAT3 in hema-
topoietic cells in tumor-bearing mice, Kortylewski et al. (27)
showed that there was marked enhancement of activated and
functional T cells, natural killer cells, and dendritic cells. STAT3
ablation in only the hematopoietic cells resulted in marked
antitumor effects in vivo , indicating that STAT3 expression in
immune cells restrains the immune cell eradication of the tumor.
Furthermore, IL-2 has been shown to regulate FoxP3 expression
in human CD4+CD25+ Tregs by inducing STAT3 binding of the
first intron of the FoxP3 gene (28). We have previously shown
that STAT3 blockade within immune cells restores immune
responses (29) and inhibits Treg induction (30).
We previously examined whether the glioma-infiltrating Treg
population acted as a prognostic marker in patients with
gliomas (31). However, we did not see a significant relationship
for glioma cell infiltration, which was likely due to the presence
of multiple redundant immunosuppressive mechanisms, in-
cluding Tregs. Recent data have emerged that p-STAT3 may be a
key component to the overall immune suppression seen in
cancer patients. Thus, the purpose of this study was to
determine the incidence of p-STAT3 expression among patients
with gliomas of various pathologic types and grades and to
determine if p-STAT3 expression was a prognostic marker,
especially because p-STAT3 confers properties of enhanced
tumorgenesis. We hypothesized that the presence of p-STAT3
would be associated with a poor prognosis within specific
glioma pathologies. Finally, we sought to determine whether p-
STAT3 expression was correlated with enhanced infiltration of
glioma by T cells and, specifically, Tregs.
Materials andMethods
Glioma tissue microarray slides. We used a previously described (32)
glioma tissue microarray (TMA) that included tissue sections from 53
patients with WHO grade IV glioblastomas (GBM), 17 with WHO grade
III anaplastic astrocytomas (AA), 3 with WHO grade II low-grade
astrocytomas, 16 with WHO grade II oligodendrogliomas, 15 with
WHO grade III anaplastic oligodendrogliomas (AO), 6 with WHO
grade II mixed oligoastrocytomas (MOA), 12 with WHO grade III
anaplastic MOAs (AMOA), and 7 with WHO grade IV gliosarcomas. The
study neuropathologist (GNF) gathered the tissue sections and
confirmed the tumor pathology based on the archived paraffin-blocked
tissue sections. The TMA also contained normal brain tissues (white
matter, cortex, and cerebellum), which were obtained from surgical
specimens, excluding autopsy specimens, containing parenchyma that
overlaid deep metastases but that were not themselves involved by the
neoplasm. We conducted our study under the institutional review
board-approved protocol LAB03-0228 at The University of Texas M. D.
Anderson Cancer Center.
Immunohistochemical analysis of p-STAT3 expression, CD3+ T cells,
CD8+ T cells, and Tregs. Formalin-fixed, paraffin-embedded sections
of the glioma TMA were first deparaffinized in xylene and rehydrated in
ethanol. We blocked the endogenous peroxidase with 0.3% hydrogen
peroxide/methanol for 10 min at room temperature before beginning
antigen retrieval. We did antigen retrieval for p-STAT3 by immersing the
sections in a citrate-buffered solution (pH 6.0) and heating the sections
in a microwave for 20 min. The sections were then cooled to room
temperature for 40 min. For antigen retrieval of FoxP3 staining, we
autoclaved the sections in 10 mmol/L citrate buffer (pH 6.0) for 10 min
at 121jC. We did antigen retrieval for CD3 and CD8 expression by
placing the sections in an electric kitchen pot filled with f800 mL of
0.05% citraconic anhydride solution (pH 7.4; Immunosaver; Nisshin
EM Co.) for 35 min at 100jC. The sections were then cooled to room
temperature for 20 min and washed 6 times in PBS solution. After
blocking with a protein block serum-free solution (DAKO), we added
diluted anti–p-STAT3 (tyrosine705) antibody (1:50; Cell Signaling
Technology), a primary antibody to CD3 (clone SK7 8-11, 1:100;
DAKO) or CD8 (clone 144B, 1:20; DAKO), or an antibody to FoxP3
(1:20; provided by Dr. Nobuyoshi Hiraoka, Pathology Division,
National Cancer Research Institute, Tokyo, Japan; ref. 33) to the tissue
arrays and incubated the specimens overnight in a humidified box at
4jC. We subjected the slides to biotin-labeled secondary antibody
staining (biotinylated link universal solution; DAKO) for 60 min at
room temperature. Finally, we added streptavidin-horseradish peroxi-
dase (DAKO) and incubated the slides for 30 min at room temperature.
We used diaminobenzidine (DAKO) as the chromogen, and we stopped
color development by gently dipping slides in distilled water. The nuclei
were then counterstained with hematoxylin. We used a human
melanoma TMA (9) as a positive control for p-STAT3 staining, and
we used MDACC banked human lymph nodes and tonsils as a positive
control for CD3, CD8, and FoxP3 staining. Omitting the primary
antibody from the immunohistochemical analysis and replacing it with
protein block serum-free solution (DAKO) acted as the negative control
for CD3 and CD8 staining. For p-STAT3 staining, we used normal goat
serum (Santa Cruz Technology) as a negative isotype control.
Three independent observers (MA-G, DSY, GNF) quantitatively
evaluated p-STAT3 expression and lymphocyte infiltration by analyzing
the cores using high-power fields (max, 40 objective and 10
eyepiece) of each specimen. The observers examined each sample in
duplicate from different areas of the same tumor in a blinded fashion.
Each observer recorded the absolute number of cells with positive
staining for p-STAT3 seen per 1-mm diameter core. The duplicate
numbers were then averaged for the final number of p-STAT3–
expressing cells and lymphocytes per surgical specimen. If there were
discrepancies between the recorded numbers, the observers recounted
the number of cells with positive staining in each specimen, and the
neuropathologist (GNF) conducted the final arbitration. We mini-
mized potential mismatching of the data by staining an intact
microarray with H&E and identifying the correct location of each
tissue core by visually matching the tumors based on their unique
histologic elements.
Translational Relevance
Signal transducer and activator of transcription (STAT3)
has been found to play a significant and varied role within
the tumor microenvironment, involving not only tumor
cells, but also the immune system through dendritic cells,T
regulatory cells (Tregs), and others as well. Our hypothesis
was that phosphorylated STAT3 (p-STAT3) expression in
human gliomas influences inflammatory responses and is
an independent negative prognostic indicator for patient
survival.This article details that p-STAT-3 expressiondiffers
between tumor pathology, is greatest in astrocytic tumors,
and is predictive of shortened overall survival (OS) in
patients with anaplastic astrocytoma. In addition, p-STAT-
3 expression closely correlates with the degree of intratu-
moralT-cell infiltration. In conclusion, p-STAT-3 is frequent-
ly observed in gliomas and represents a viable therapeutic
target for a variety of small-molecule inhibitors of p-STAT-3
that are in preclinical development.
p-STAT3 Expression in Gliomas
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Statistical analysis. We conducted an equal proportion examination
of tumor grade, pathologic tumor type, and glial lineage (astrocytic
versus oligodendroglial; ref. 34). We calculated the Kaplan-Meier
product-limit OS probability estimates (35) and did log-rank tests
(36) to determine whether there was an association between OS and
p-STAT3 expression (versus none), tumor grade, astrocytic and
oligodendroglial lineage, and age. For each fitted OS regression model,
we eliminated the nonsignificant variables in a step-down fashion using
a P value cutoff of 0.10. A P value of <0.05 was considered significant.
Results
Study population. Tissue sections from 129 patients with
gliomas were included in the TMA. The median age of the
patients was 44 years (range, 4-91 years). Most patients (97%)
had a Karnofsky performance score of z70, with a median
Karnofsky performance score of 90 at the time of diagnosis
(range, 50-100). Table 1 summarizes the patients’ demographic
characteristics and is stratified according to the patients’
pathologic diagnoses, age, Karnofsky performance score, and
OS time. The patients’ demographic characteristics in our study
did not differ significantly from the demographic characteristics
of patients with gliomas in previous studies examining
prognostic markers (32, 37, 38). Of the GBM and AA cases,
19 (36%) and 6 (35%) were recurrent, respectively. Of the
patients with GBM, 9 (17%) had received prior chemotherapy
and 11 (21%) had received prior radiation therapy. Table 2
summarizes the overall composition of the glioma TMA, and
Fig. 1 shows the immunohistochemical staining of p-STAT3
and CD3+ T-cell infiltration.
Incidence of p-STAT3 expression varies according to tumor
grade in astrocytomas. To determine whether oligodendroglio-
mas and astrocytomas expressed p-STAT3, we stained the tumor
specimens with an anti–p-STAT3 antibody and determined the
number of cells with positive nuclear staining. We did not
observe p-STAT3 expression in the normal brain tissue speci-
mens (n = 5) or in the patients with WHO grade II low-grade
astrocytomas (n = 3; Table 3; Fig. 1). In patients with WHO
grade III AAs (n = 17), 9 (53%) expressed p-STAT3, and in
patients with WHO grade IV GBMs or gliosarcomas (n = 60),
32 (53%) expressed p-STAT3.
We did not observe an increase in p-STAT3 expression
corresponding with an increase in tumor grade in either the
oligodendrogliomas or MOAs. Specifically, 38% of the patients
with WHO grade II oligodendrogliomas (n = 16) had p-STAT3
expression, and 40% of the patients with WHO grade III AOs
(n = 15) had p-STAT3 expression, indicating the incidence of
p-STAT3 expression did not increase with increasing tumor
grade in oligodendrogliomas. This trend is further supported by
our finding that 100% of the patients with WHO grade II MOAs
(n = 6) hadp-STAT3 expression,whereas only 58%of the patients
with WHO grade III AMOAs (n = 12) had p-STAT3 expression.
Incidence of p-STAT 3 expression varies according to tumor
pathology. We observed significant differences in p-STAT3
expression according to the pathologic type of the tumor.
Specifically, the presence of any p-STAT3 staining was most
often observed in MOAs (100%), followed by GBMs (53%) and
AAs (53%; Table 3; Fig. 1). The pathologic types with the lowest
incidence of p-STAT3 staining were low-grade astrocytomas
(0%) followed by oligodendrogliomas (38%; Table 3).
Number of p-STAT3–expressing cells varies according to tumor
grade in astrocytomas and oligodendrogliomas. Although the
incidence of p-STAT3 expression was not significantly different
between patients with WHO grade III AAs and patients with
WHO grade IV GBMs, the number of cells within the gliomas
that expressed p-STAT3 increased. Specifically, in patients
with WHO grade II low-grade astrocytomas, there were no
p-STAT3–expressing cells per core, which increased to a mean
of 5.6 p-STAT3–expressing cells per core (SD, 7.6; range,
0-23.0) for patients with WHO grade III AAs, and 11.7 cells per
core (SD, 24.4; range, 0-133.5) for patients with WHO grade IV
GBMs. Similarly, among patients with WHO grade II oligoden-
drogliomas, there was a mean of 4.3 cells per core (SD, 7.7;
Table 1. Demographic characteristics of patients with glioma stratified according to pathology
Pathology Age (y) KPS Median survival time (mo)*
Median Minimum Maximum Median Minimum Maximum
O 38.5 7.0 55.0 100 80 100 99.8
MOA 42.5 24.0 52.0 100 70 100 —c
AO 40.0 25.0 59.0 90 70 100 —c
AMOA 35.5 22.0 47.0 100 80 100 89.2
LGA 33.0 4.0 44.0 95 90 100 166.7
AA 49.0 24.0 91.0 90 90 100 27.7
GS 51.0 23.0 68.0 80 60 100 4.4
GBM 56.0 17.0 77.0 90 50 100 13.8
Abbreviations: GS, gliosarcoma; KPS, Karnofsky performance score; LGA, low-grade astrocytoma.
*Based on Kaplan-Meier estimates.
cNot analyzed due to rarity.
Table 2. Composition of the glioma TMA
Lineage Pathology No. of patients (%)
Oligodendroglial (n = 49) O 16 (12.4%)
MOA 6 (4.7%)
AO 15 (11.6%)
AMOA 12 (9.3%)
Astrocytic (n = 80) LGA 3 (2.3%)
AA 17 (13.2%)
GS 7 (5.4%)
GBM 53 (41.1%)
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range, 0-23.5), which increased to 17.5 cells per core (SD, 41.0;
range, 0-153.0) for patients with WHO grade III AOs. This
propensity did not hold true for the patients with WHO grade II
MOAs, in whom the mean was 67.9 cells per core (SD, 55.2;
range, 9.0-136.0), when compared with patients with WHO
grade III AMOAs, in whom the mean was 13.3 cells per core
(SD, 27.0; range, 0-85.5).
Correlation of p-STAT3 expression and T-cell infiltration.
Across all tumor pathologies and tumor grades, increased
p-STAT3 expression was associated with an increase in glioma-
infiltrating T cells. In the pair-wise scatter plots with Loess
smooth curves examining the relationship between p-STAT3
expression and CD3+ and CD8+ T-cell infiltration, an almost
straight trend indicated that there was a strong linear corre-
Fig.1. Immunohistochemical staining of human glioma tissue sections demonstrating p-STAT3 and CD3+ lymphoid cells.The p-STAT3 stainingwas confined to the nucleus,
whereas CD3 staining was noted on the cell surface. A , the number of p-STAT3^ expressing cells was more evident in astrocytic, higher-grade gliomas. B, CD3 staining
showed high numbers of infiltrative CD3+ Tcells, also within higher-glioma grades. All images were taken at a magnification of400. Normal brain (a), low-grade
astrocytoma (b), AA (c), GBMmultiforme (d), oligodendroglioma (e), MOA (f), AO (g), and AMOA (h).
Table 3. Proportion of p-STAT3–positive cases according to pathology and WHO tumor grade
Pathology p-STAT3 >0/total (%) Mean (SD)* (Minimum, maximum)
O 6/16 (38%) 4.3 (7.7) (0.0, 23.5)
MOA 6/6 (100%) 67.9 (55.2) (9.0, 136.0)
AO 6/15 (40%) 17.5 (41.0) (0.0,153.0)
AMOA 7/12 (58%) 13.3 (27.0) (0.0, 85.5)
LGA 0/3 (0%) 0 0
AA 9/17 (53%) 5.6 (7.6) (0.0, 23.0)
GS 5/7 (71%) 23.1 (34.1) (0.0, 91.0)
GBM 27/53 (51%) 11.7 (24.4) (0.0, 133.5)
*The mean calculation was based on the mean p-STAT3 value.
p-STAT3 Expression in Gliomas
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lation between CD3+ and CD8+ T-cell infiltration and p-STAT3
expression (P < 0.001 for both; Fig. 2).
Lack of correlation between p-STAT3 expression and Treg
infiltration. To determine if there was an association between
p-STAT3 expression and the presence of Tregs, we stained the
glioma TMA with FoxP3 (31). Within the GBM specimens that
expressed p-STAT3, 59% (16 of 27) had an infiltrating Treg
population. However, the level of p-STAT3 expression was not
associated with the number of infiltrating Tregs. In the MOA,
AMOA, and AO specimens, in which there was a high incidence
of p-STAT3–expressing cells, there was no correlating Treg
glioma-infiltrating population. Thus, the presence of p-STAT3
within the tumor does not seem to be a key regulator of the
presence or degree of the tumor infiltrating Treg population.
p-STAT-3 expression level is a prognostic marker for survival
times. Among the patients with gliomas with no p-STAT3
expression, regardless of the specific tumor pathology, the
median survival time was 34.6 months [95% confidence
interval (CI), 19.2 months to not estimable]. In contrast, for
patients with gliomas with p-STAT3 expression, the median
survival time was 20.1 months (95% CI, 13.8-43.0 months);
however, this was not statistically significant (Fig. 3A).
For patients with GBMs and p-STAT3 expression, the median
survival time was 10.7 months (95% CI, 7.5-15.0 months),
whereas the median survival time was 18.1 months (95% CI,
6.6-41.8 months) for patients with GBMs without p-STAT3
expression; however, this was not statistically significant
(Fig. 3B). In patients with AAs expressing p-STAT3, the median
survival time was 12.2 months (95% CI, 6.2 months to NA),
whereas the median survival time was 34.6 months (95% CI,
33.9 months to NA) for patients with AAs that lacked p-STAT3
expression (P = 0.02; Fig. 3C). On univariate analysis, the
presence of p-STAT3 (P = 0.04; hazard ratio, 5.94) in patients
with AAs was a prognostic factor. However, after adjusting for
age in the multivariate analysis, the presence of p-STAT3 was
only marginally significant (P = 0.06; hazard ratio 5.32), which
could be due to our limited sample size. All AA patients under-
went combinational radiation and chemotherapy. The absolute
number of p-STAT3–expressing cells did not have a prognostic
effect for patients with AAs on either univariate or multivariate
analyses. In addition, p-STAT3 expression did not seem to be a
prognostic factor in patients with either AOs or oligodendro-
gliomas. Because there was no p-STAT3 expression in low-grade
gliomas and all MOAs expressed p-STAT3, no prognostic signi-
ficance for survival can be ascertained within these pathologic
subtypes. Removing GBMs and AAs with prior radiotherapy
or chemotherapy (i.e., recurrent) from our analysis did not
have a statistically significant effect on our results.
Discussion
In this study, we found that p-STAT3 is commonly expressed
in a variety of gliomas. Furthermore, as astrocytomas become
more malignant, the number of p-STAT3–expressing cells
increases. We frequently observed p-STAT3–expressing cells in
GBMs, gliosarcomas, and AAs, but we did not see significant
p-STAT3 expression in normal brain tissues or low-grade
gliomas. Because we used a glioma TMA that contains only a
small proportion of the overall tumor, we cannot completely
exclude the possibility that p-STAT3–expressing cells were
present in the low-grade tumors and normal tissue. However,
in an attempt to negate this as a possibility, we used duplicate
tissue cores from different areas of the tumors and normal
tissue from various CNS anatomic positions in the TMA.
Investigators have examined p-STAT3 expression in other
malignancies, such as gastric (39), renal (40), ovarian (41),
squamous (42, 43), and hepatocellular carcinomas (44) and
anaplastic large-cell lymphoma (45, 46), and have determined
that p-STAT3 expression was associated with poor prognosis.
Other studies have also shown that p-STAT3 expression
correlated with lymph node spread of colorectal cancer (47)
and the depth of tumor invasion (48). However, some studies
found no relationship between p-STAT3 expression and prog-
nosis in patients with non–small cell lung cancer (49, 50).
Although these studies addressed p-STAT3 expression at the
tyrosine705 location, similar to our current study, another group
found that p-STAT3 at the serine727 location correlated with
the degree of cervical intraepithelial neoplasia (51). Similar to
most studies examining the prognostic significance of p-STAT3
expression, we found on univariate analysis that in AAs,
p-STAT3 expression was a negative prognostic factor.
Our study is in stark contrast, however, to a previous study in
which a similar glioma microarray was used, which found that
<10% of p-STAT3 expression at tyrosine705 occurred in gliomas
Fig. 2. Pair-wise scatter plots between p-STAT3, CD3,
and CD8 across all tumor pathologies and tumor grades
with Loess smooth curves added.The almost straight
trend of the Loess curves indicates that both CD3 and
CD8 had a strong linear correlation with p-STAT3
expression. Specifically, the correlation of the number of
p-STAT3 expressing cells with the number of tumor
infiltrating CD3+ Tcells was 0.99 (P < 0.001) and with
the number of tumor infiltrating CD8+ Tcells was 0.94
(P < 0.001).
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of all grades and pathologic types (52). The potential reasons
for the difference between this previous study and our current
study may include our process for antigen retrieval and the
titration of the primary antibody. Because very little p-STAT3
expression was seen in the previous study, the authors did not
attempt to correlate p-STAT3 expression with prognosis.
However, another immunohistochemical study of p-STAT3
expression in just GBMs and AAs found an almost identical
incidence of p-STAT3 expression (i.e., 55.6% in AAs and 56.4%
in GBMs; ref. 53) as in our current study. In this latter study, the
authors saw a trend that activated STAT3 conferred a survival
advantage, but this was not statistically significant. The
difference between the results of our current study and the
results of the previous study may be due to the sample set but,
most likely, it is attributed to the analysis. In the study by
Mizoguchi et al. (53), the association for prognosis was with
activation of STAT3 alone and not activation of STAT3 in
general. More specifically, they compared cases having only
STAT3 activation against those cases containing combinations
of STAT3/MAPK/AKT activation. Since they observed a corre-
lation of AKT activation with a worse prognosis, it was not
surprising that the cases with worse survival would fall into the
combined activation group in their analyses and that STAT3
activation alone would not be a negative prognostic factor.6
This study also showed a correlation between STAT3 activation
and epidermal growth factor receptor status that was attributed
exclusively to epidermal growth factor receptor vIII expression.
We also found that in gliomas with p-STAT3 expression,
there was a statistically significant corresponding influx of
CD3+ T cells. Because IL-6 is expressed in the CNS under a wide
variety of conditions and has been shown to attract T cells to
the CNS, it was not surprising that the amount of p-STAT3
expression directly correlated with the number of CD3+
glioma-infiltrating T cells. One needs to bear in mind, however,
that the presence of infiltrating T cells does not correlate
with their having functional activity (54). The tumor microen-
vironment induces STAT3 activity in tumor-associated immune
cells (25, 27), and the induced p-STAT3 in the tumor-
infiltrating immune cells resulted in their functional down
modulation (21–24, 27, 29). Thus, although STAT3 expression
in the tumor correlates with the degree of immune infiltration
in the tumor microenvironment, it has also likely resulted in
their immune suppression. This may partially resolve the
divergent findings of various studies that have examined the
prognostic effects of glioma infiltrating T-cell populations on
prognosis (55–57).
Investigators have reported the presence FoxP3+ Tregs in a
variety of cancers, including hepatocellular carcinoma, colo-
rectal cancer, ovarian cancer, and others (32, 58–62). Studies
Fig. 3. Kaplan-Meier survival estimates stratified by the presence or
absence of p-STAT3 immunohistochemical staining within all patients
with gliomas, patients with GBM, and patients with AA. A, among all
patients with gliomas without p-STAT3 expression, the median survival
time was 34.6 mo (95% CI, 19.2, mo to NA) and 20.1mo (95% CI,
13.8-43.0 mo) in patients with gliomas with p-STAT3 expression
(P = 0.16). B, in patients with GBMmultiforme without p-STAT3
expression, the median survival time was18.1mo (95% CI, 6.6-41.8 mo)
and10.7mo (95%CI, 7.5-15.0mo) in patientswith GBMmultiformewith
p-STAT3 expression (P = 0.12). C, in patients with AA patients without
p-STAT3 expression, the median survival time was 34.6 mo (95% CI,
33.9 mo to NA) and12.2 mo (95% CI, 6.2 mo to NA) in patients with
AAwith p-STAT3 expression (P = 0.02).
6 C.L. Nutt, personal correspondence, October 31, 2008.
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have shown that the presence of FoxP3+ Tregs in ovarian cancer
is not only a predictor of poor prognosis but also an
independent predictor of OS and progression-free survival
times (58, 59). However, in anal squamous cell carcinoma, the
presence of Tregs did not have a prognostic influence (63). We
examined FoxP3 expression in gliomas and did not find it to be
an independent negative prognostic factor for median survival
time (31). Within some pathologies, such as oligodendrogliomas,
we did not observe the presence of FoxP3 despite the presence
of p-STAT3 expression. Conversely, we identified Treg infiltra-
tion in tumors without p-STAT3 expression. Thus, although p-
STAT3 may be a transcriptional factor related to the induction
of FoxP3 expression, it may not be the only factor that
influences Treg generation.
Because p-STAT3 is frequently observed in gliomas, it
represents a viable target for a variety of small-molecule
inhibitors of p-STAT3, such as WP1066 (14, 29), JSI-124
(cucurbitacin I; ref. 64), and S3I-201 (65), which are in various
stages of preclinical development. However, the variability of
p-STAT3 expression within the various glioma pathologies
suggests that not all patients may uniformly benefit from
treatment with these types of anti–p-STAT3 approaches. Future
studies will be directed at evaluating the in vivo effects of
small molecule inhibitors of p-STAT3 in preclinical models
of intracerebral gliomas with variable expression levels of
p-STAT3. In conclusion, p-STAT3 is frequently expressed among
patients with high grade gliomas, MOA and AMOA, has a
prognostic influence within patients with AAs, and its
expression correlates with enhanced T-cell infiltration within
gliomas.
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